At a glance
- Originator Zeria
- Developer Nippon Chemiphar; Zeria
- Class Hepatoprotectants
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Liver disorders
Most Recent Events
- 06 Jul 2001 Discontinued-Preclinical for Liver disorders in Japan (Unknown route)
- 21 Jul 2000 New profile
- 21 Jul 2000 Preclinical development for Liver disorders in Japan (Unknown route)